GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » LifeMD Inc (NAS:LFMD) » Definitions » Debt-to-EBITDA

LFMD (LifeMD) Debt-to-EBITDA : -2.95 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is LifeMD Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

LifeMD's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.7 Mil. LifeMD's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $19.5 Mil. LifeMD's annualized EBITDA for the quarter that ended in Sep. 2024 was $-8.5 Mil. LifeMD's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -2.95.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for LifeMD's Debt-to-EBITDA or its related term are showing as below:

LFMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.48   Med: -0.13   Max: -0.02
Current: -2.48

During the past 13 years, the highest Debt-to-EBITDA Ratio of LifeMD was -0.02. The lowest was -2.48. And the median was -0.13.

LFMD's Debt-to-EBITDA is ranked worse than
100% of 445 companies
in the Healthcare Providers & Services industry
Industry Median: 2.45 vs LFMD: -2.48

LifeMD Debt-to-EBITDA Historical Data

The historical data trend for LifeMD's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LifeMD Debt-to-EBITDA Chart

LifeMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.33 -0.02 -0.04 -0.12 -2.40

LifeMD Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.78 50.35 -1.22 -1.30 -2.95

Competitive Comparison of LifeMD's Debt-to-EBITDA

For the Health Information Services subindustry, LifeMD's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LifeMD's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, LifeMD's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where LifeMD's Debt-to-EBITDA falls into.



LifeMD Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

LifeMD's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.931 + 18.002) / -7.889
=-2.40

LifeMD's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.681 + 19.463) / -8.516
=-2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


LifeMD  (NAS:LFMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


LifeMD Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of LifeMD's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeMD Business Description

Traded in Other Exchanges
N/A
Address
236 Fifth Avenue, Suite 400, Fourth Floor, New York, NY, USA, 10001
LifeMD Inc is a direct-to-patient telehealth company that provides a smarter, cost-effective, and more convenient way of accessing comprehensive, virtual healthcare. Its telehealth platform seamlessly integrates a clinician-centric electronic medical record (EMR) system, proprietary algorithms for case-load balancing and scheduling, customer relationship management functionality, remote and in-home lab testing, and digital prescription capabilities, patient-provider audio/video interfacing, cloud pharmacy fulfillment, and more. In addition to telehealth offerings, the company sells nutritional supplements and other over-the-counter products. The company has two operating segments: Telehealth and WorkSimpli. The company generates the majority of its revenue from the Telehealth segment.
Executives
Justin Schreiber director, 10 percent owner, officer: President, Immudyne PR 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Stefan Galluppi director, officer: Chief Operating Officer C/O LIFEMD, INC, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Bertrand Velge director BARNHOUSE FARM, BARNHOUSE LANE BROOKLAND, ROMNEY MARSH, KENT X0 TN299TR
William J Febbo director, other: Consultant 600 CALIFORNIA ST., 9TH FLOOR, SAN FRANCISCO CA 94108
Nicholas P Alvarez officer: Chief Acquisition Officer C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Eric Harold Yecies officer: CCO and General Counsel C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Brad Michael Roberts officer: Chief Operating Officer 300 CHAFFORD COURT, SIMPSONVILLE SC 29681
Joan Larovere director C/O LIFEMD, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Jessica Friedeman officer: Chief Marketing Officer C/O LIFEMD, 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Kathleen E Walsh director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Piyush Jindal director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Joseph Ditrolio director C/O LIFEMD, INC., 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Maria E. Stan officer: Principal Accounting Officer 236 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Dennis Wijnker officer: Chief Technology Officer 536 FIFTH AVENUE, SUITE 400, NEW YORK NY 10001
Naveen Bhatia director 823 GREENTREE RD, PACIFIC PALISADES CA 90272